Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Xencor, Inc. (NASDAQ:XNCR) has received an average rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $24.8750.

XNCR has been the topic of several recent analyst reports. JPMorgan Chase & Co. reduced their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Wedbush reiterated an “outperform” rating and issued a $26.00 target price on shares of Xencor in a research note on Thursday, November 6th. Barclays boosted their target price on shares of Xencor from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Cantor Fitzgerald raised their price target on shares of Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th.

Xencor Trading Down 0.4%

Shares of NASDAQ:XNCR opened at $11.54 on Friday. Xencor has a 12 month low of $6.92 and a 12 month high of $18.69. The company has a market capitalization of $824.07 million, a price-to-earnings ratio of -6.52 and a beta of 0.98. The firm’s 50-day moving average is $13.85 and its 200 day moving average is $12.60.

Insider Buying and Selling

In other news, VP John R. Desjarlais sold 73,367 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the transaction, the vice president owned 236,574 shares of the company’s stock, valued at approximately $3,718,943.28. This represents a 23.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.71, for a total value of $1,796,862.67. Following the transaction, the chief executive officer owned 466,635 shares in the company, valued at approximately $7,330,835.85. This represents a 19.69% decrease in their position. The disclosure for this sale is available in the SEC filing. 5.23% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Primecap Management Co. CA lifted its position in shares of Xencor by 1.4% in the 3rd quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares during the period. Vanguard Group Inc. raised its stake in Xencor by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after buying an additional 61,692 shares in the last quarter. State Street Corp lifted its holdings in Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after buying an additional 833,423 shares during the period. Geode Capital Management LLC boosted its position in Xencor by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 1,752,918 shares of the biopharmaceutical company’s stock valued at $26,842,000 after acquiring an additional 24,093 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Xencor by 2.8% in the 4th quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock valued at $20,027,000 after acquiring an additional 35,088 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.